Related Experiment Video

Updated: May 23, 2026

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection
05:57

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope?

Michael Berger1, Benno Ure, Martin Lacher

  • 1Virgen del Rocío Children's Hospital, Seville, Spain.

European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [Et Al] = Zeitschrift Fur Kinderchirurgie
|April 21, 2012
PubMed

Insights

Topical Mitomycin C shows promising results for treating pediatric esophageal strictures, offering relief in most cases. Further research is needed to optimize this novel treatment approach for children.

Area of Science:

  • Pediatric Gastroenterology
  • Otolaryngology
  • Surgical Innovation

Background:

  • Esophageal strictures pose a significant challenge in pediatric care, especially when resistant to standard treatments.
  • Topical Mitomycin C is an emerging therapy for these refractory cases, but clinical experience is limited.

Purpose of the Study:

  • To systematically review the existing literature on the topical application of Mitomycin C in children with persistent esophageal strictures.
  • To evaluate the efficacy and safety of Mitomycin C for pediatric esophageal stricture treatment.

Main Methods:

  • A systematic review of 11 publications encompassing 31 pediatric cases of esophageal stricture.
  • Analysis of underlying causes, treatment techniques (e.g., endoscopic application, drug-eluting stents), Mitomycin C concentrations, and application frequency.
  • Evaluation of patient outcomes and adverse events following treatment.

Main Results:

  • The primary causes of stricture were caustic ingestion (61.2%) and esophageal surgery (22.6%).
  • Complete symptom relief was achieved in 67.7% of cases, with partial relief in 19.4%. Treatment failure occurred in 12.9%.
  • No direct or indirect adverse effects were reported, suggesting a favorable safety profile.

Conclusions:

  • Short-term outcomes of topical Mitomycin C for refractory pediatric esophageal strictures are highly encouraging.
  • Prospective studies are essential to establish optimal treatment parameters, including dosage, timing, and application methods, before widespread recommendation.
Abstract

More Related Videos

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy04:05

Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy

Published on: August 22, 2025

Related Concept Videos

Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Esophageal Strictures-I: Introduction01:30

Esophageal Strictures-I: Introduction

Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...